Sanofi Loses Bid To Stay Launch Of Generic Eloxatin
A judge has denied Sanofi-Aventis US LLC's request to stay the launch of generic versions of its popular colon cancer drug Eloxatin pending appeal of a finding of noninfringement in Sanofi's...To view the full article, register now.
Already a subscriber? Click here to view full article